Uterine fibroids do not become cancerous in the vast majority of cases, even after menopause. The overall rate of a cancerous tumor (called a leiomyosarcoma) being found during surgery for what was thought to be a fibroid is roughly 1 in 2,000 procedures. That said, the risk is not zero, and it rises with age, which is why postmenopausal fibroids deserve closer monitoring than those found in younger women.
How Fibroids and Uterine Cancer Are Related
Fibroids (leiomyomas) are benign muscle tumors of the uterus. Leiomyosarcomas are rare, aggressive cancers that also arise in uterine muscle. For years, doctors debated whether sarcomas develop independently or whether a benign fibroid can transform into one. Case reports have documented a transition zone where benign fibroid tissue merges into cancerous tissue under the microscope, suggesting that transformation from fibroid to sarcoma is possible in rare instances. However, most experts believe the vast majority of leiomyosarcomas arise on their own rather than evolving from an existing fibroid.
A large meta-analysis pooling data from 64 high-quality studies estimated the rate of hidden leiomyosarcoma at roughly 1 per 8,300 surgeries performed for presumed fibroids. That is far lower than earlier estimates that had put the figure closer to 1 in 350. In practical terms, the chance that any individual fibroid harbors cancer is extremely small.
Why Age Matters
While the overall number is reassuring, the risk is not evenly distributed across age groups. In women under 40, the rate of an occult malignancy at fibroid surgery is about 1 in 1,572. In women over 65, it jumps to roughly 1 in 33. That dramatic difference is the reason clinicians take postmenopausal fibroids more seriously. A fibroid that was stable for decades and suddenly begins to grow after menopause, when estrogen levels have dropped and fibroids typically shrink, raises more concern than one behaving the same way in a 35-year-old.
The Role of Hormone Replacement Therapy
One complicating factor is hormone replacement therapy (HRT). A three-year study of postmenopausal women found that HRT can cause fibroids to grow, particularly in the first two years of use. Fibroid volume increased significantly in HRT users during years one and two, then began to plateau and decline in year three. In the control group (no HRT), fibroids also grew slightly in the first year but returned to baseline by year three.
This matters because growth of a fibroid after menopause is one of the signals that prompts doctors to investigate further. If you are on HRT and your fibroid grows modestly, that growth may be hormone-driven and benign. But if growth is rapid or accompanied by other symptoms, it warrants closer evaluation regardless of HRT use.
Warning Signs to Watch For
Uterine sarcoma shares symptoms with several common, noncancerous conditions, which is part of what makes it difficult to detect early. The key symptoms include:
- Vaginal bleeding after menopause: any amount of bleeding after your periods have fully stopped
- Unusual vaginal discharge
- A mass or lump felt in the vagina
- Pelvic pain that is new or worsening
- A feeling of fullness or pressure in the abdomen
None of these symptoms are unique to cancer. Postmenopausal bleeding, for example, has benign causes in the majority of cases. But postmenopausal bleeding always deserves medical evaluation because it is the most common early sign of uterine malignancies.
How Doctors Tell Fibroids From Cancer
Distinguishing a benign fibroid from a sarcoma before surgery is one of the genuine challenges in gynecology. On a standard MRI, a typical fibroid has a distinct, low-signal appearance that looks quite different from a sarcoma, which tends to show areas of internal bleeding and tissue death. The problem is that large fibroids often undergo a process called degeneration, where they outgrow their blood supply and develop internal changes that can look almost identical to cancer on imaging.
Blood tests can add another piece to the puzzle. Levels of a common enzyme called LDH are significantly higher in women with sarcomas compared to those with degenerating fibroids. One study found that using an LDH cutoff of about 187 U/L could identify sarcomas with roughly 73% sensitivity and 87% specificity. Two other blood markers, CA-125 and HE4, were also elevated in sarcoma patients. None of these tests are definitive on their own, but together with imaging and clinical history, they help doctors assess risk.
The reality is that a definitive answer usually requires examining the tissue itself. This is one reason that the surgical approach matters.
Why the Surgical Approach Matters
Power morcellation is a technique used during minimally invasive surgery to break a large fibroid into smaller pieces so it can be removed through a small incision. If the tissue turns out to be cancerous, morcellation can scatter malignant cells throughout the abdomen, significantly worsening outcomes. One study found that women who had an unsuspected sarcoma morcellated during laparoscopic surgery had a recurrence-free survival of just 11 months, compared to 40 months for women who had the tumor removed intact through open surgery.
This risk is especially relevant for postmenopausal women given their higher baseline probability of hidden malignancy. The concern led the FDA to issue safety warnings about power morcellation, and many surgeons now avoid uncontained morcellation entirely in older patients. If you are postmenopausal and facing surgery for fibroids, it is reasonable to discuss with your surgeon how the tissue will be removed and whether morcellation is being considered.
What This Means in Practice
If you are postmenopausal and have known fibroids, the most important thing is to pay attention to changes. Fibroids that remain stable in size and cause no symptoms generally do not require intervention. The situations that call for further investigation include rapid growth (especially without HRT), new or worsening pelvic symptoms, and any vaginal bleeding.
Routine monitoring with pelvic ultrasound can track whether fibroids are stable or changing. If there is any suspicion, an MRI with contrast and blood work can help clarify the picture before any surgical decisions are made. For the vast majority of postmenopausal women with fibroids, the answer to “could this be cancer?” is no. But the small, age-dependent increase in risk means that staying aware of changes and following up on new symptoms is genuinely worthwhile.